FDA has accepted a supplemental new drug application for Zejula (niraparib) as maintenance treatment in the first-line setting for women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
